On Monday, TD Cowen expressed continued confidence in Abbott Laboratories (NYSE:ABT), maintaining a Buy rating and a $135.00 price target on the company’s shares. With a market capitalization of $220.6 billion and a P/E ratio of 16.5, Abbott trades near its InvestingPro Fair Value. The endorsement comes despite recent market reactions to a meeting between RFK Jr. and baby food manufacturers, followed by a press release on the new Health and Human Services (HHS)/Food and Drug Administration (FDA) "Operation Stork Speed" initiative for U.S. infant formulas.
Analysts at TD Cowen believe that Abbott Labs is already in compliance with, if not exceeding, the standards and priorities set by the Operation Stork Speed program. They argue that the initiative is highly unlikely to present any new challenges to Abbott Labs’ formula business. The company’s stock had experienced a sell-off earlier in the week, following the announcement of the initiative.
Abbott Labs has reported a stable supply of infant formula, describing its current situation as "smooth sailing." The company, which generated $42 billion in revenue over the last twelve months and maintains strong financial health according to InvestingPro metrics, has been operating at full capacity for multiple quarters, following the events that impacted its Sturgis, Michigan, facility in 2022. TD Cowen’s analysts see no current need for improvement in the U.S. infant formula supply, though they acknowledge the significance of maintaining an adequate supply, which has been highlighted as a priority by Operation Stork Speed. InvestingPro analysis reveals Abbott as a prominent player in the Healthcare Equipment & Supplies industry, with 11 consecutive years of dividend increases and consistently low price volatility.
The positive outlook from TD Cowen suggests that Abbott Labs is well-positioned to continue its operations without interruption from the new government initiative. The company’s ability to maintain full production capacity post the 2022 Sturgis plant issues appears to have contributed to the analyst firm’s reiteration of a Buy rating and a confident price target for Abbott Labs’ stock. For deeper insights into Abbott’s financial health, valuation metrics, and growth potential, access the comprehensive Pro Research Report available exclusively on InvestingPro.
In other recent news, Abbott Laboratories has received FDA approval for an investigational device exemption for its Coronary Intravascular Lithotripsy (IVL) System. This approval allows the commencement of the TECTONIC clinical trial, which will evaluate the system’s efficacy in treating severe arterial calcification in patients with Coronary Artery Disease. The trial will enroll up to 335 participants across 47 U.S. sites. Meanwhile, BofA Securities and Citi have both maintained Buy ratings on Abbott’s stock, with price targets of $150 and $160, respectively, despite ongoing legal challenges. These challenges include a retrial order in the Whitfield infant formula case, which had initially ruled in favor of Abbott. The retrial could extend the legal process by up to two years. Analysts from BofA and Citi have highlighted Abbott’s strong fundamentals and durable revenue growth, noting that the company remains a strong performer in the medical technology sector. The ongoing legal developments have, however, cast a shadow over the stock, with investors closely monitoring the situation.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.